Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • The company has solid fundamentals for a short-term investment strategy.
Strengths
  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at EUR 101.65 EUR in weekly data.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 14.03 for the current year.
  • For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The group usually releases earnings worse than estimated.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
BAYER6.02%103 473
JOHNSON & JOHNSON24.03%380 546
NOVARTIS13.16%222 673
PFIZER12.81%217 327
ROCHE HOLDING LTD.3.91%211 657
MERCK AND COMPANY-4.86%152 759
AMGEN21.32%126 976
SANOFI-4.07%109 810
NOVO NORDISK A/S32.08%104 507
BRISTOL-MYERS SQUIBB COMPAN..8.61%101 688
ABBOTT LABORATORIES43.35%95 263
ELI LILLY AND COMPANY19.50%95 245
GLAXOSMITHKLINE-17.38%85 328
CELGENE CORPORATION-6.52%85 219
ASTRAZENECA10.07%82 972
ALLERGAN PLC-19.41%56 852
More Results
Financials (€)
Sales 2017 35 679 M
EBIT 2017 7 597 M
Net income 2017 6 179 M
Debt 2017 8 778 M
Yield 2017 2,46%
P/E ratio 2017 14,03
P/E ratio 2018 18,35
EV / Sales 2017 2,71x
EV / Sales 2018 2,48x
Capitalization 88 070 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart BAYER
Duration : Period : Day
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Duration : Period : Week
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders